Pyruvate attenuates the anti-neoplastic effect of carnosine independently from oxidative phosphorylation

  title={Pyruvate attenuates the anti-neoplastic effect of carnosine independently from oxidative phosphorylation},
  author={Henry Oppermann and Lutz Schnabel and J{\"u}rgen Meixensberger and Frank Gaunitz},
  pages={85848 - 85860}
Here we analyzed whether the anti-neoplastic effect of carnosine, which inhibits glycolytic ATP production, can be antagonized by ATP production via oxidative phosphorylation fueled by pyruvate. Therefore, glioblastoma cells were cultivated in medium supplemented with glucose, galactose or pyruvate and in the presence or absence of carnosine. CPI-613 was employed to inhibit the entry of pyruvate into the tricarboxylic acid cycle and 2,4-dinitrophenol to inhibit oxidative phosphorylation. Energy… 

Figures and Tables from this paper

Carnosine influences transcription via epigenetic regulation as demonstrated by enhanced histone acetylation of the pyruvate dehydrogenase kinase 4 promoter in glioblastoma cells

It is demonstrated for the first time that carnosine influences epigenetic regulation via increased histone acetylation in glioblastoma cell lines U87 and T98G.

Krebs cycle: activators, inhibitors and their roles in the modulation of carcinogenesis

To determine the particularities in the energy metabolism of cancer cells, focusing on the main nutritional substrates, such as glucose and glutamine, evaluating lactate dehydrogenase as a potential marker of malignancy and estimating activators and inhibitors in cancer treatment is determined.

Carnosine inhibits glioblastoma growth independent from PI3K/Akt/mTOR signaling

Carnosine’s anti-neoplastic effect is independent from PI3K/Akt/mTOR signaling and should be considered for therapy, especially as it is a naturally occurring compound that has already been used for the treatment of other diseases without indication of side-effects.

Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer

CP-613, a novel lipoate analog, redirects cellular activity towards tumor-promoting glutaminolysis, leading to low anticancer efficacy in head and neck squamous cell carcinoma cells, and the addition of a GLS1 inhibitor CB-839 to CPI-613 treatment abrogates the metabolic dependency of HNSCC cells on glutamine, achieving a synergistic anticancer effect in glutamine-addicted H NSCC.

Carnosine selectively inhibits migration of IDH-wildtype glioblastoma cells in a co-culture model with fibroblasts

It is demonstrated that the anti-proliferative effect of carnosine is not accompanied by an induction of cell migration, and the dipeptide is able to prevent colony formation and selectively eliminates tumor cells in a co-culture with fibroblasts.

L-Carnosine Stimulation of Coenzyme Q10 Biosynthesis Promotes Improved Mitochondrial Function and Decreases Hepatic Steatosis in Diabetic Conditions

This work suggests that carnosine exerts beneficial effects on hepatic CoQ synthesis and when combined with CoQ, improves mitochondrial function and cellular redox balance in the liver of diabetic mice.

The proton-coupled oligopeptide transporters PEPT2, PHT1 and PHT2 mediate the uptake of carnosine in glioblastoma cells

It is demonstrated that the transporters PEPT2, PHT1, and PHT2 are responsible for the uptake of carnosine into glioblastoma cells and full function of all threetransporters is required for maximum uptake.

Erythrocytes Prevent Degradation of Carnosine by Human Serum Carnosinase

It is demonstrated for the first time that erythrocytes can take up carnosine, and, most importantly, thereby prevent its degradation by human serum carnosinase.

Therapeutic potential of carnosine and its derivatives in the treatment of human diseases.

Despite significant progress in the pathogenesis, diagnosis, treatment and prevention of cancer and neu-rodegenerative diseases, their occurence and mortality is still high around the world. The

Targeting Altered Energy Metabolism in Colorectal Cancer: Oncogenic Reprogramming, the Central Role of the TCA Cycle and Therapeutic Opportunities

The identified cancer-specific metabolic transformations provided new therapeutic targets for the development of small molecule inhibitors, including α-lipoic acid derivative CPI-613, an inhibitor of both PDC and KGDH, and delineate its anti-tumor effects for targeted therapy.



Carnosine inhibits ATP production in cells from malignant glioma

Carnosine might be considered as a potential drug for the treatment of malignant glioma or other tumors since it inhibits the glycolytic energy metabolism that is crucial for cancer cells and malignantgliomas as shown in the current study.

Carnosine Inhibits the Proliferation of Human Gastric Cancer SGC-7901 Cells through Both of the Mitochondrial Respiration and Glycolysis Pathways

The results suggested that carnosine is a potential regulator of energy metabolism of SGC-7901 cells both in the anaerobic and aerobic pathways, and provided a clue for preclinical and clinical evaluation of carnosines for gastric cancer therapy.

Carnosine Inhibits Growth of Cells Isolated from Human Glioblastoma Multiforme

Since carnosine is a naturally occurring substance that appears to be non-toxic to normal tissue and is able to penetrate the blood–brain barrier it may be a candidate for a therapeutic agent that may reduce proliferation of neoplastic cells even in vivo and especially in cases of glioblastoma multiforme.

The antineoplastic effect of carnosine is accompanied by induction of PDK4 and can be mimicked by l-histidine

Enhanced expression of PDK4 under the influence of carnosine/l-histidine opens a new perspective for the interpretation of the ergogenic potential of dietary β-alanine supplementation and adds a new contribution to a growing body of evidence that single amino acids can regulate key metabolic pathways important in health and disease.

Inhibition of the growth of transformed and neoplastic cells by the dipeptide carnosine.

Mixtures of normal MRC-5 fibroblasts and HeLa cells are used to demonstrate that 20 mM carnosine can selectively eliminate the tumour cells, and it is proposed that it depletes certain glycolysis intermediates.

The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth

It is demonstrated that M2 expression is necessary for aerobic glycolysis and that this metabolic phenotype provides a selective growth advantage for tumour cells in vivo.

Metabolic response of glioblastoma cells associated with glucose withdrawal and pyruvate substitution as revealed by GC-MS

A high plasticity of glioblastoma cells to changes in nutritional supply is revealed which has to be taken into account in clinical trials in which specific diets are considered for therapy.

Inhibition of tumour cell growth by carnosine: some possible mechanisms

It is possible, by acting at various sites that this pluripotent dipeptide may be an example of an endogenous “smart drug”, which would decrease ATP supply and generation of metabolic intermediates required for continued cell reproduction.

Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo

We report the analysis of CPI-613, the first member of a large set of analogs of lipoic acid (lipoate) we have investigated as potential anticancer agents. CPI-613 strongly disrupts mitochondrial

Carnosine Inhibits the Proliferation of Human Gastric Carcinoma Cells by Retarding Akt/mTOR/p70S6K Signaling

The results showed that treatment with carnosine led to proliferation inhibition, cell cycle arrest in the G0/G1 phase, apoptosis increase, and inhibition of mTOR signaling activation by decreasing the phosphorylation of Akt, mTOR and p70S6K, suggesting that proliferation inhibition of Carnosine in human gastric carcinoma was through the inhibition ofAkt/mTOR/p70S 6K pathway, and Carnival would be a mimic of rapamycin.